Intensive care unit—acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shock
Open Access
- 17 December 2010
- journal article
- research article
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 1 (2), 147-157
- https://doi.org/10.1007/s13539-010-0010-6
Abstract
Sepsis presents a major health care problem and remains one of the leading causes of death within the intensive care unit (ICU). Therapeutic approaches against severe sepsis and septic shock focus on early identification. Adequate source control, administration of antibiotics, preload optimization by fluid resuscitation and further hemodynamic stabilisation using vasopressors whenever appropriate are considered pivotal within the early—golden—hours of sepsis. However, organ dysfunction develops frequently in and represents a significant comorbidity of sepsis. A considerable amount of patients with sepsis will show signs of severe muscle wasting and/or ICU-acquired weakness (ICUAW), which describes a frequently observed complication in critically ill patients and refers to clinically weak ICU patients in whom there is no plausible aetiology other than critical illness. Some authors consider ICUAW as neuromuscular organ failure, caused by dysfunction of the motor unit, which consists of peripheral nerve, neuromuscular junction and skeletal muscle fibre. Electrophysiologic and/or biopsy studies facilitate further subclassification of ICUAW as critical illness myopathy, critical illness polyneuropathy or critical illness myoneuropathy, their combination. ICUAW may protract weaning from mechanical ventilation and impede rehabilitation measures, resulting in increased morbidity and mortality. This review provides an insight on the available literature on sepsis-mediated muscle wasting, ICUAW and their potential pathomechanisms.Keywords
This publication has 119 references indexed in Scilit:
- Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and MuscleJournal of Cachexia, Sarcopenia and Muscle, 2010
- During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylationThe Journal of cell biology, 2009
- Neuromuscular Electrical Stimulation Reduces Skeletal Muscle Protein Degradation and Stimulates Insulin-Like Growth Factors in an Age- and Current-Dependent MannerAnnals of Surgery, 2009
- The initiation factor eIF3-f is a major target for Atrogin1/MAFbx function in skeletal muscle atrophyThe EMBO Journal, 2008
- Trauma and Hemorrhage-Induced Acute Hepatic Insulin Resistance: Dominant Role of Tumor Necrosis Factor-αEndocrinology, 2008
- The E3 Ligase MuRF1 Degrades Myosin Heavy Chain Protein in Dexamethasone-Treated Skeletal MuscleCell Metabolism, 2007
- Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic reviewCritical Care, 2007
- The Pathophysiology and Treatment of SepsisThe New England Journal of Medicine, 2003
- American College of Chest Physicians/Society of Critical Care Medicine Consensus ConferenceCritical Care Medicine, 1992
- Stimulation of Muscle Protein Degradation and Prostaglandin E2Release by Leukocytic Pyrogen (Interleukin-1)The New England Journal of Medicine, 1983